Artiva Biotherapeutics, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $21.5 million, compared to a net loss of $17.5 million for the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $63.1 million, up from $49.3 million in the prior year. The increase in losses is attributed to higher operating expenses, which rose to $22.9 million in Q3 2025 from $18.3 million in Q3 2024, driven primarily by increased research and development costs associated with the ongoing clinical trials of its lead product candidate, AlloNK.
Artiva's total operating expenses for the nine months ended September 30, 2025, reached $67.9 million, a substantial increase from $49.3 million in the same period of 2024. The rise in expenses was largely due to a $15.5 million increase in research and development costs, reflecting the company's focus on advancing its NK cell-based therapies. The company did not generate any revenue from product sales during this period, maintaining its reliance on external funding to support its operations.
In terms of strategic developments, Artiva has made notable progress in its clinical trials. The company announced the treatment of its first patient in a global Phase 2a basket trial for AlloNK in combination with rituximab for refractory rheumatoid arthritis and other autoimmune diseases. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AlloNK for this indication, which is expected to expedite its development process. As of November 2025, 32 patients have been treated with AlloNK across various trials, and the company plans to share initial safety and translational data soon.
Operationally, Artiva's cash and cash equivalents stood at $25.5 million as of September 30, 2025, down from $40.2 million at the end of 2024. The company has raised a total of $441.7 million since its inception, primarily through its IPO and other financing activities. Despite the decrease in cash reserves, Artiva believes its existing funds will be sufficient to support operations for at least the next year. The company is also exploring additional funding options, including an at-the-market offering program that could raise up to $11.95 million.
Looking ahead, Artiva anticipates continued significant losses as it advances its clinical programs and builds its operational capabilities. The company is focused on securing additional funding to support its research and development efforts and is preparing for potential commercialization activities if its product candidates receive regulatory approval. The future capital requirements will depend on various factors, including the progress of clinical trials, manufacturing costs, and the overall market conditions.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics develops off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its lead candidate, AlloNK, enhances antibody-dependent cellular cytotoxicity (ADCC) in combination with B-cell targeted monoclonal antibodies, aiming to deplete pathogenic B-cells. The company focuses on scalable manufacturing, outpatient administration, and broad indications, leveraging proprietary processes and strategic collaborations to deliver accessible, safe, and effective cell therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.